ARCHIVES

Jako Bows Out with Blast At NCI, Calls For IOM Review Of Cancer Program

This article is from The Cancer Letter archive.

Vol. 14 No. 16 | April 15, 1988

Download PDF Visit The Full Archive

Related Articles

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

ODAC Recommends Fludarabine Approval for Refractory CLL

September 21, 1990

Sirolimus-Containing Therapy Reduces GVHD, Study Finds

January 31, 2003

NCAB Committee Reaches Consensus On Organ Systems; DeVita Goes Along

February 4, 1983

Reviewers Report Progress In New Drug Prescreen System Development, Commend DTP

December 15, 1989

NCI Programs: Contract Awarded For Geographic Information System

May 14, 1999